Boston Scientific Corporation reported robust Q2 2024 financial results with net sales reaching $4.120 billion, up 14.5% from $3.599 billion in Q2 2023. The growth included 16.1% operational growth and a negative 160 basis point impact from foreign currency fluctuations. Reported net income attributable to Boston Scientific common stockholders was $324 million, or $0.22 per diluted share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 20.1% increase to $2.047 billion, while MedSurg segment sales rose 9.0% to $1.483 billion. Emerging Markets revenue grew 14.8% on a reported basis, with strong performance in China.Looking ahead, Boston Scientific announced agreements to acquire Silk Road Medical for $1.26 billion and Axonics for $3.67 billion, both expected to close in second half 2024. The company maintains a strong financial position with $2.913 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management remains focused on strategic growth initiatives while navigating global supply chain and economic challenges.

Boston Scientific Corporation reported robust Q2 2024 financial results with net sales reaching $4.120 billion, up 14.5% from $3.599 billion in Q2 2023. The growth included 16.1% operational growth and a negative 160 basis point impact from foreign currency fluctuations. Reported net income attributable to Boston Scientific common stockholders was $324 million, or $0.22 per diluted share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 20.1% increase to $2.047 billion, while MedSurg segment sales rose 9.0% to $1.483 billion. Emerging Markets revenue grew 14.8% on a reported basis, with strong performance in China.Looking ahead, Boston Scientific announced agreements to acquire Silk Road Medical for $1.26 billion and Axonics for $3.67 billion, both expected to close in second half 2024. The company maintains a strong financial position with $2.913 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management remains focused on strategic growth initiatives while navigating global supply chain and economic challenges.